Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Skin, Subcutaneous Tissue and BreastDRG 596-major-skin-disorders-without-mcc
    Ask Trek AI about this page

    Major Skin Disorders without MCC: Inpatient Reimbursement Overview

    DRG 596 addresses major skin and subcutaneous tissue disorders without a Major Complication or Comorbidity, encompassing serious infections, extensive wounds, and other significant dermatologic conditions that require inpatient care. Correct grouping into this Diagnosis-Related Group is important because it determines Medicare inpatient reimbursement by reflecting expected resource use for these cases.

    Customize your policy alerts

    Sign up for drg 596 policy alerts

    Get alerted when payer policies referencing 596 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 596 Overview

    DRG 596 covers major skin and subcutaneous tissue disorders without a Major Complication or Comorbidity and typically includes serious dermatologic conditions requiring inpatient medical or surgical management, such as extensive cellulitis, severe ulcerations, major skin infections, and large nonhealing wounds. This Diagnosis-Related Group groups hospital stays by clinical similarity and expected resource use, which determines Medicare payment rates for inpatient episodes. Accurate coding and documentation of diagnoses and procedures affect assignment to DRG 596 and therefore influence reimbursement. The classification distinguishes cases without a Major Complication or Comorbidity from higher-severity Diagnosis-Related Groups that command higher payment adjustments.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute inpatient therapeutic trials evaluating rapid-acting anti-inflammatory or wound-healing interventions for severe skin disorders: these studies enroll hospitalized adults with major dermatologic conditions such as extensive cellulitis, severe ulcerations, or acute inflammatory dermatoses requiring inpatient care, testing interventions intended to reduce lesion size, control infection, or accelerate re-epithelialization within the admission window. Results inform clinicians about interventions that can shorten length of stay and reduce complication rates, and inform payers about potential cost savings from therapies that decrease inpatient resource utilization and readmission risk.
    • Comparative effectiveness studies of systemic versus targeted or adjunctive therapies during the index admission: trials compare standard systemic management (for example, broad-spectrum antibiotics or systemic anti-inflammatory regimens) with alternative strategies such as more targeted biologic approaches, optimized antimicrobial stewardship protocols, or multimodal supportive care bundles in patients admitted for major skin disorders without major complications. These studies focus on clinical outcomes (resolution, adverse events), utilization metrics (ICU transfer, LOS), and cost-effectiveness, providing evidence relevant to hospital formularies, care pathways, and payer coverage decisions for therapies used in the inpatient setting.
    • Post-discharge outcomes and coordination-of-care research assessing transition-of-care interventions and readmission prevention in patients discharged after major skin disorder hospitalization: prospective cohort studies or randomized pragmatic trials evaluate discharge planning, outpatient wound care programs, telemedicine follow-up, and adherence support in patients with extensive skin disease or healing wounds. This research targets reducing 30- and 90-day readmissions, preventing wound-related complications, and measuring downstream costs and quality-of-life outcomes, which are critical for providers and payers focused on bundled payments, readmission penalties, and long-term cost containment.

    Related Codes

    570-SKIN-DEBRIDEMENT-WITH-MCC

    Skin Debridement with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    571-SKIN-DEBRIDEMENT-WITH-CC

    Skin Debridement with CC: Inpatient Reimbursement Overview

    572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

    Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

    573-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    574-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    575-SKIN-GRAFT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    576-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis with MCC: Inpatient Reimbursement Overview

    577-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITH-CC

    Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

    578-SKIN-GRAFT-EXCEPT-FOR-SKIN-ULCER-OR-CELLULITIS-WITHOUT-CC-MCC

    Skin Graft Except for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

    579-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-MCC

    Other Skin, Subcutaneous Tissue and Breast Procedures with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 31

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.